AME Stock Analysis: Ametek | NYSE

Specialty Industrial Machinery | NYSE, USA | Market Cap: 55.520m USD | 12M Return: 24.1% | US0311001004 | Charts, Fundamentals & Technical Analysis

Aerospace Sensors, Medical Devices, Process Instruments, Specialty Metals
Total Rating 62
Safety 84
Buy Signal -0.02
Electrical Components & Equipment
Sub-Industry Rotation: -17.2
Market Cap: 55.5B
Avg Turnover: 382M
Risk 3d forecast
Volatility32.0%
VaR 5th Pctl5.35%
VaR vs Median1.66%
Reward TTM
Sharpe Ratio0.79
Rel. Str. IBD54.3
Rel. Str. Peer Group75 pctl
Character TTM
Beta0.904
Beta Downside0.726
Hurst Exponent0.492
Choppyness78.6%
Drawdowns 3y
Max DD23.04%
CAGR/Max DD0.69
CAGR/Mean DD2.85
EPS (Earnings per Share) EPS (Earnings per Share) of AME over the last years for every Quarter: "2021-09": 1.26, "2021-12": 1.37, "2022-03": 1.33, "2022-06": 1.38, "2022-09": 1.45, "2022-12": 1.52, "2023-03": 1.49, "2023-06": 1.57, "2023-09": 1.64, "2023-12": 1.68, "2024-03": 1.64, "2024-06": 1.66, "2024-09": 1.66, "2024-12": 1.87, "2025-03": 1.75, "2025-06": 1.78, "2025-09": 1.89, "2025-12": 2.01, "2026-03": 1.97, "2026-06": 2.09, "2026-09": 2.21,
EPS CAGR: 9.42%
EPS Trend: 98.3%
Last SUE: 2.61
Qual. Beats: 17
Revenue Revenue of AME over the last years for every Quarter: 2021-09: 1440.681, 2021-12: 1503.745, 2022-03: 1458.525, 2022-06: 1514.552, 2022-09: 1551.786, 2022-12: 1625.667, 2023-03: 1597.117, 2023-06: 1646.111, 2023-09: 1622.837, 2023-12: 1730.885, 2024-03: 1736.18, 2024-06: 1734.834, 2024-09: 1708.564, 2024-12: 1761.602, 2025-03: 1731.971, 2025-06: 1778.056, 2025-09: 1892.641, 2025-12: 1998.448, 2026-03: 1928.437, 2026-06: 2044.397, 2026-09: 2220.306,
Rev. CAGR: 7.20%
Rev. Trend: 94.7%
Last SUE: 1.77
Qual. Beats: 2

Warnings

Choppy
Below Avwap Earnings

Tailwinds

Seasonal Tailwind
Confidence

Seasonality 11.9 years of data, until 10/2026

Jan +0.6% 0
Feb +1.8% 4
Mar -0.8% 4
Apr -1.4% 4
May +1.5% 4
Jun -1.0% 14
Jul +0.3% 4
Aug -1.6% 14
Sep -1.8% 14
Oct +0.4% 4
Nov ★ +5.5% 64
Dec -0.9% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: AME Ametek

AMETEK (NYSE: AME) is a global manufacturer of electronic instruments and electromechanical devices, operating through two segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). Its products serve a diversified set of end markets, including process, aerospace, power, oil and gas, petrochemical, pharmaceutical, semiconductor, automation, food and beverage, laboratory equipment, medical, test and measurement, and defense. The company also runs a network of aviation maintenance, repair, and overhaul (MRO) facilities, giving it exposure to aftermarket services in addition to its core manufacturing business. AMETEKs broad portfolio spans precision motion control products, thermal management systems, specialty metals, engineered connectors, medical components, and sensors for aircraft and heavy vehicles.

The company is classified within the GICS Industrials sector, specifically in the Electrical Components & Equipment sub-industry, reflecting its focus on niche, technology-driven manufacturing rather than commodity production. AMETEKs business model is built on a combination of organic growth and acquisitions, a common strategy among diversified industrial conglomerates that allows it to expand into adjacent high-margin, specialized markets. Founded in 1930 and headquartered in Berwyn, Pennsylvania, AMETEK has grown into a large-cap industrial with a market capitalization of roughly $57 billion, supported by long-standing customer relationships in highly regulated and technically demanding industries.

Headlines to Watch Out For
  • Accretive niche acquisitions sustain margin expansion
  • Aerospace and defense backlog drives EIG segment revenue
  • Medical and semiconductor end markets accelerate order growth
Piotroski VR-10 (Strict) 5.5
Net Income: 1.63b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.52 > 1.0
NWC/Revenue: 13.88% < 20% (prev 5.75%; Δ 8.13% < -1%)
CFO/TA 0.09 > 3% & CFO 2.08b > Net Income 1.63b
Net Debt (6.36b) to EBITDA (2.53b): 2.52 < 3
Current Ratio: 1.43 > 1.5 & < 3
Outstanding Shares: last quarter (230.0m) vs 12m ago -0.70% < -2%
Gross Margin: 36.64% > 18% (prev 36.18%; Δ 0.46% > 0.5%)
Asset Turnover: 42.48% > 50% (prev 44.27%; Δ -1.80% > 0%)
Interest Coverage Ratio: 18.42 > 6 (EBIT TTM 2.09b / Interest Expense TTM 113.7m)
Altman Z'' 4.14
A: 0.05 (Total Current Assets 3.78b - Total Current Liabilities 2.64b) / Total Assets 22.4b
B: 0.59 (Retained Earnings 13.3b / Total Assets 22.4b)
C: 0.11 (EBIT TTM 2.09b / Avg Total Assets 19.3b)
D: 1.09 (Book Value of Equity 11.7b / Total Liabilities 10.7b)
Altman-Z'' = 4.14 = AA
Beneish M -2.99
DSRI: 0.90 (Receivables 1.35b/1.31b, Revenue 8.19b/7.16b)
GMI: 0.99 (GM 36.18% / 36.64%)
AQI: 1.05 (AQ_t 0.78 / AQ_t-1 0.74)
SGI: 1.14 (Revenue 8.19b / 7.16b)
TATA: -0.02 (NI 1.63b - CFO 2.08b) / TA 22.4b)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of AME shares?

As of November 17, 2026, the stock is trading at USD 235.75 with a total of 1,380,681 shares traded. Over the past week, the price has changed by -1.05%, over one month by -5.00%, over three months by -7.11% and over the past year by +24.06%.

Current recommended Stop Loss: 224.80 (which is 4.6% or 1.5 ATR below the current price).

Is AME a buy, sell or hold?

Ametek has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy AME.

  • StrongBuy: 12
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the AME price?
Analysts Target Price 288.8 22.5%
Ametek (AME) - Fundamental Data Overview as of 17 November 2026
Market Cap USD = 55.5b (55.5b USD * 1.0 USD.USD)
P/E Trailing = 34.1481
P/E Forward = 27.3973
P/S = 6.7777
P/B = 4.7469
P/EG = 2.7236
Revenue TTM = 8.19b USD
EBIT TTM = 2.09b USD
EBITDA TTM = 2.53b USD
Long Term Debt = 6.03b USD (from longTermDebt, last quarter)
Short Term Debt = 713.5m USD (from shortTermDebt, last quarter)
Debt = 7.03b USD (from shortLongTermDebtTotal, last quarter) + Leases 61.1m
Net Debt = 6.36b USD (calculated: Debt 7.03b - CCE 666.2m)
Enterprise Value = 61.9b USD (55.5b + Debt 7.03b - CCE 666.2m)
Interest Coverage Ratio = 18.42 (Ebit TTM 2.09b / Interest Expense TTM 113.7m)
EV/FCF = 32.02x (Enterprise Value 61.9b / FCF TTM 1.93b)
FCF Yield = 3.12% (FCF TTM 1.93b / Enterprise Value 61.9b)
FCF Margin = 23.59% (FCF TTM 1.93b / Revenue TTM 8.19b)
Net Margin = 19.91% (Net Income TTM 1.63b / Revenue TTM 8.19b)
Gross Margin = 36.64% ((Revenue TTM 8.19b - Cost of Revenue TTM 5.19b) / Revenue TTM)
Gross Margin QoQ = 36.50% (prev 35.95%)
Tobins Q-Ratio = 2.76 (Enterprise Value 61.9b / Total Assets 22.4b)
Interest Expense / Debt = 1.62% (Interest Expense 113.7m / Debt 7.03b)
Taxrate = 17.67% (350.1m / 1.98b)
NOPAT = 1.72b (EBIT 2.09b * (1 - 17.67%))
Current Ratio = 1.43 (Total Current Assets 3.78b / Total Current Liabilities 2.64b)
Debt / Equity = 0.60 (Debt 7.03b / totalStockholderEquity, last quarter 11.7b)
Debt / EBITDA = 2.52 (Net Debt 6.36b / EBITDA 2.53b)
Debt / FCF = 3.29 (Net Debt 6.36b / FCF TTM 1.93b)
Total Stockholder Equity = 11.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.46% (Net Income 1.63b / Total Assets 22.4b)
RoE = 14.66% (Net Income TTM 1.63b / Total Stockholder Equity 11.1b)
RoCE = 12.21% (EBIT 2.09b / Capital Employed (Equity 11.1b + L.T.Debt 6.03b))
RoIC = 8.60% (NOPAT 1.72b / Invested Capital 20.1b)
WACC = 7.85% (E(55.5b)/V(62.5b) * Re(8.68%) + D(7.03b)/V(62.5b) * Rd(1.62%) * (1-Tc(0.18)))
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.79 | Cagr: -0.43%
[DCF] Terminal Value 77.97% ; FCFF base≈1.82b ; Y1≈2.08b ; Y5≈3.06b
[DCF] Fair Price = 173.4 (EV 46.1b - Net Debt 6.36b = Equity 39.8b / Shares 229.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.35 | EPS CAGR: 9.42% | SUE: 2.61 | # QB: 17
Revenue Correlation: 94.72 | Revenue CAGR: 7.20% | SUE: 1.77 | # QB: 2
EPS current Quarter (2027-03-31): EPS=2.25 | Chg30d=+0.30% | Revisions=+17% | Analysts=14
EPS current Year (2026-12-31): EPS=8.56 | Chg30d=+2.34% | Revisions=+79% | GrowthEPS=+15.2% | GrowthRev=+16.3%
EPS next Year (2027-12-31): EPS=9.64 | Chg30d=+1.34% | Revisions=+55% | GrowthEPS=+12.6% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: +72% (up=20, down=2)